Navigation Links
Lexicon to Provide Third Quarter 2012 Financial Results
Date:10/31/2012

THE WOODLANDS, Texas, Oct. 31, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it will release its third quarter 2012 financial results on Tuesday, November 6, 2012 before the financial markets open.  Lexicon management will hold a conference call and webcast to discuss financial results for the quarter and program status at 11:00 a.m. Eastern Time that same day.

The dial-in number for the conference call is 888-645-5785 (within the US/Canada) or 970-300-1531 (international).  The conference ID for all callers is 59736084.  Investors can access a live webcast of the call at www.lexpharma.com.  An archived version of the webcast will be available on Lexicon's corporate website at www.lexpharma.com through December 6, 2012.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic allianc
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lexicon to Provide First Quarter 2012 Financial Results
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
4. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
5. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
6. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Lexicon to Provide Second Quarter 2012 Financial Results
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
10. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
11. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 InfinityQS ... and Manufacturing Intelligence , today announces Infusion ... The event will be held Oct. 9-10, 2014, ... is designed to showcase the necessity for implementing ... metrics and Manufacturing Intelligence to gain insight into ...
(Date:8/21/2014)... -- Professional Compounding Centers of America (PCCA) will ... three best scientific presentations at the sixth ... Formulating Better Medicines for Children  conference, held ... Greece , includes dozens of poster-style scientific ... three winners will be selected by a panel ...
(Date:8/21/2014)... MENLO PARK, Calif. , Aug. 21, 2014 /PRNewswire/ ... company in the emerging field of regenerative medicine, announced ... ("Nat") Ricciardi to the Company,s newly expanded Board of ... now comprises eight directors, three of whom are independent. ... years of experience working with emerging growth companies. He ...
Breaking Medicine Technology:InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4
(Date:8/21/2014)... College of Chest Physicians (CHEST) announces the immediate ... Injured During Pandemics and Disasters: CHEST Consensus Statement ... journal CHEST while the global health-care ... The consensus statement aims to guide ethical decision-making, ... crises. The statement was developed by over 100 ...
(Date:8/21/2014)... (Aug. 21, 2014) An international scientific collaboration led ... genetic alterations that may contribute to a rare form ... this rare cancer but other types as well. , ... Health,s Cancer Genome Atlas initiative , completed the ... results today in the journal Cancer Cell . ...
(Date:8/21/2014)... Utah scientists have developed a genetically engineered line of ... new research on epilepsy, Alzheimer,s and other diseases. ... in degree of fluorescence in response to different calcium ... called astrocytes and microglia, to be studied in a ... to decipher how the brain works," said Petr ...
(Date:8/21/2014)... The Mount Sinai Hospital has expanded its ... captures real-time patient feedback and enables staff to make ... now available to admitted patients in the Hospital’s cardiology, ... satisfaction using smartphones. , "We are expanding our ... the timely information we need to respond to patient ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Greater awareness ... to have babies before they are full term has ... some areas of the country, early elective deliveries (EEDs) ... last 20 years, EED is defined as delivery before ... linked to neonatal morbidity and mortality, and offers no ...
Breaking Medicine News(10 mins):Health News:CHEST releases new expert guidance in care of the critically ill and injured 2Health News:Sequence of rare kidney cancer reveals unique alterations involving telomerase 2Health News:Sequence of rare kidney cancer reveals unique alterations involving telomerase 3Health News:Mouse model for epilepsy, Alzheimer's gives window into the working brain 2Health News:The Mount Sinai Hospital Expands Use of Mobile Patient Satisfaction Tool 2Health News:The Mount Sinai Hospital Expands Use of Mobile Patient Satisfaction Tool 3Health News:New “Playbook” Aims to Eliminate Early Elective Deliveries in the United States 2Health News:New “Playbook” Aims to Eliminate Early Elective Deliveries in the United States 3
... window of vulnerability for developing binge eating disorder, especially ... study from the University of North Carolina at Chapel ... long-term study of 100,000 pregnant Norwegian women, the researchers ... eating disorder that began during pregnancy. The research is ...
... By furthering scientists understanding of the molecular mechanisms that ... majority of ineffective antibodies, the work may have implications ... The study was published on September 6, 2007, in ... of the effort to understand how protection against HIV ...
... to Peter B. Ajluni, D.O., American Osteopathic,Association (AOA) President, ... of,Americans without health insurance to 47 million --- as ... --- is a disturbing trend signaling,more must be done ... As lawmakers return this week from the summer recess, ...
... Sept. 6 H.E.A.R.T 911 is a,non-profit, non-sectarian ... fighters and construction trade union workers, all of,whom ... 11th attacks and,surviving family members of those who ... nation-wide to situations that arise during,natural or man-made ...
... promotes free quit-smoking services from ClearWay ... ... a,dramatic new billboard will catch the eye of motorists on Interstate ... a,giant ashtray, the billboard will call attention to QUITPLAN(R) Services,Clearway Minnesota,s ...
... Interactive Workshop Features CML Expert, Jorge Cortes, M.D., ... an,expert on leukemia, will discuss novel treatment approaches for ... CML: A,Model in Cancer Therapy. The program is scheduled ... ET. The program is being offered by The ...
Cached Medicine News:Health News:Pregnancy may increase the risk of developing binge eating disorder 2Health News:Scripps Research scientists shed new light on how antibodies fight HIV 2Health News:Scripps Research scientists shed new light on how antibodies fight HIV 3Health News:Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911. 2Health News:Award-winning QUITPLAN(R) Services Billboard Debuts in Rogers 2Health News:The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia 2Health News:The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: